Hormonal therapy for endometriosis: from molecular research to bedside

Claudia Tosti, Antonella Biscione, Biscione A, Giuseppe Morgante, Giuseppe Bifulco, Stefano Luisi, Felice Petraglia, Petraglia F
European journal of obstetrics, gynecology, and reproductive biology · 2016 · vol. 209 , pp. 61–66 · doi:10.1016/j.ejogrb.2016.05.032 · PMID:27503693 · W2399797665
review OA: green CC0 ⤵ 75 in-corpus citations
🔓 Open OA copy View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-08 ⓘ

This review covers hormonal therapy for endometriosis, exploring its molecular mechanisms and clinical applications for patient treatment.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Endometriotic lesions are associated with hormonal imbalance, including increased estrogen synthesis, metabolism and progesterone resistance. These hormonal changes cause increased proliferation, inflammation, pain and infertility. Hormonal imbalances are targets for treatment. Therapeutic strategies and innovations of hormonal drugs for endometriosis are increasing. Acting on estrogen receptors are hormonal drugs decreasing systemic and local estrogen synthesis (GnRH analogs, GnRH antagonists, Aromatase inhibitors) or estrogen activity (selective estrogen receptor modulators). The progesterone resistance is counteracted by progestins (Medroxyprogesterone acetate, Dienogest, Danazol, Levonorgestrel) or by Selective progesterone receptor modulators, a class of drugs under development. The future trend will be to define new drugs to use for prolonged period of time and with poor side effects considering endometriosis a chronic disease.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Aromatase Inhibitors Endometriosis Hormone Antagonists Levonorgestrel Medroxyprogesterone Acetate Selective Estrogen Receptor Modulators Aromatase Inhibitors Endometriosis Female Hormone Antagonists Humans Levonorgestrel Medroxyprogesterone Acetate Selective Estrogen Receptor Modulators Treatment Outcome

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (98)

Cited by (50)

Source provenance

europepmc
last seen: 2026-07-27T06:15:28.040536+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:20:54.390225+00:00
License: CC0 · commercial use OK